Treatment of prostate cancer in patients aged 75 or olderTabei, ToshioOgita, MasamiHirata, KouichiSatomi, SusumuKimura, MichioAbe, RikiyaMorishita, YasuoKimura, MorihikoAndou, JirouHigashi, Yasuhiro
abiraterone acetate (AA) in ≥ 85 year-old patients with advanced castrate-resistant prostate cancer (CRPC).Patients received 750 mg oral AA as three 250-mg tablets once daily, with concomitant oral prednisone, 5 mg daily.Twenty-six patients were enrolled; median age was 88 years (range=85...
EP: 1.A 75-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer EP: 2.Treatment Options for Patients With Metastatic Castration-Resistant Prostate Cancer EP: 3.CARD Trial: Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer ...
"We found that the percentage of men who received treatment for their prostate cancer treatments increased over time from 61.2% to 67.6% from 1998 through 2007," said Gross, who is a member of Yale Cancer Center. "However, we were surprised to find that the biggest increase was among men ...
BroderickHannah Clarke January 1st 2025 Top 10 prostate cancer articles and videos of 2024 By Benjamin P. Saylor December 28th 2024 FDA reports Urgent Field Safety Notice on mini PCNL sheath By Hannah Clarke December 21st 2024 Latest CME Events & Activities Oncology Decoded Live! Advancing Peri-...
aIn the case of the 67-year old pensioner with prostate cancer, associated with severe lumbar pain, metastases were excluded with great certainty. Orthopedic treatment in the form of injections, infusions and medication was rather unsuccessful. Periradicular therapy carried out by a radiologist under...
NEW YORK -- Researchers have found long-term evidence that actively monitoring localized prostate cancer is a safe alternative to immediate surgery or radiation. The results, released Saturday, are encouraging for men who want to avoid treatment-related sexual and incontinence problems, said Dr. Stac...
The ZERO Prostate Cancer Support Community connects patients, families, friends and caregivers to enhance the quality of life for all those affected by prostate cancer. This community is sponsored by ZERO Prostate Cancer, an Inspire trusted partner.
In an interview with Targeted OncologyTM, Chaudry discussed the evolving landscape of prostate cancer treatment, driven by new research. Targeted Oncology: In your opinion, what have been some of the most impactful data and research in the prostate cancer space over the past year or so? Chaudry...
PURPOSE: Overtreatment of screen-detected localized prostate cancer (LPC) is an important public health concern, since the survival benefit of aggressive treatment (surgery or radiation) has not been well established. We investigated the survival expectations of patients who had LPC with and without ...